IKT
Inhibikase Therapeutics Inc
NASDAQ: IKT · HEALTHCARE · BIOTECHNOLOGY
$1.93
-0.52% today
Updated 2026-05-05
Market cap
$254.82M
P/E ratio
—
P/S ratio
10.39x
EPS (TTM)
$-0.49
Dividend yield
—
52W range
$1 – $2
Volume
1.4M
Inhibikase Therapeutics Inc (IKT) Financial statements
SEC filings — annual and quarterly data.
Balance sheet — annual
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|
| Total assets | $162927.00 | $285167.00 | $2.85M | $38254.00 | $14.78M | $42.47M | $24.94M | $14.51M | $98.60M |
| Cash & equivalents | $12036.00 | $16665.00 | $379557.00 | $18457.00 | $13.95M | $40.75M | $7.19M | $9.17M | $56.49M |
| Current assets | $80164.00 | $198070.00 | $1.25M | $35381.00 | $14.78M | $42.47M | $24.37M | $14.21M | $98.45M |
| Total liabilities | $1.51M | $1.73M | $3.62M | $4.53M | $5.00M | $4.05M | $3.90M | $3.53M | $3.73M |
| Current liabilities | $1.51M | $1.73M | $3.62M | $4.25M | $4.72M | $4.05M | $3.70M | $3.44M | $3.73M |
| Long-term debt | — | — | — | $275375.00 | $276461.00 | — | — | — | — |
| Shareholder equity | $-1.35M | $-1.44M | $-777965.00 | $-4.49M | $9.78M | $38.42M | $21.04M | $10.98M | $94.87M |
| Retained earnings | $-3.87M | $-4.31M | $-6.46M | $-12.18M | $-15.03M | $-29.82M | $-47.87M | $-66.90M | $-94.42M |
| Accounts receivable | $66878.00 | $180780.00 | $472941.00 | — | $0.00 | $110141.00 | $39881.00 | $39881.00 | — |
| Inventory | $0.00 | — | — | — | — | $107000.00 | $1.12M | $1.12M | — |
| Goodwill | — | — | — | — | — | — | — | — | — |